Lymphocyte profile in peripheral blood of patients with multiple myeloma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F24%3A10480940" target="_blank" >RIV/00669806:_____/24:10480940 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11140/24:10480940

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=OvFok~ioCi" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=OvFok~ioCi</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00277-024-05820-x" target="_blank" >10.1007/s00277-024-05820-x</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Lymphocyte profile in peripheral blood of patients with multiple myeloma

Popis výsledku v původním jazyce

Multiple myeloma (MM) is a disease which remains incurable. One of the main reasons is a weakened immune system that allows MM cells to survive. Therefore, the current research is focused on the study of immune system imbalance in MM to find the most effective immunotherapy strategies. Aiming to identify the key points of immune failure in MM patients, we analysed peripheral lymphocytes subsets from MM patients (n = 57) at various stages of the disease course and healthy individuals (HI, n = 15) focusing on T, NK, iNKT, B cells and NK-cell cytokines. Our analysis revealed that MM patients exhibited immune alterations in all studied immune subsets. Compared to HI, MM patients had a significantly lower proportion of CD4 + T cells (19.55% vs. 40.85%; p &lt; 0.001) and CD4 + iNKT cells (18.8% vs. 40%; p &lt; 0.001), within B cells an increased proportion of CD21LCD38L subset (4.5% vs. 0.4%; p &lt; 0.01) and decreased level of memory cells (unswitched 6.1% vs. 14.7%; p &lt; 0.001 and switched 7.8% vs. 11.2%; NS), NK cells displaying signs of activation and exhaustion characterised by a more than 2-fold increase in SLAMF7 MFI (p &lt; 0.001), decreased expression of NKG2D (MFI) and NKp46 (%) on CD16 + 56 + and CD16 + 56- subset respectively (p &lt; 0.05), Effective immunotherapy needs to consider these immune defects and monitoring of the immune status of MM patients is essential to define better interventions in the future.

Název v anglickém jazyce

Lymphocyte profile in peripheral blood of patients with multiple myeloma

Popis výsledku anglicky

Multiple myeloma (MM) is a disease which remains incurable. One of the main reasons is a weakened immune system that allows MM cells to survive. Therefore, the current research is focused on the study of immune system imbalance in MM to find the most effective immunotherapy strategies. Aiming to identify the key points of immune failure in MM patients, we analysed peripheral lymphocytes subsets from MM patients (n = 57) at various stages of the disease course and healthy individuals (HI, n = 15) focusing on T, NK, iNKT, B cells and NK-cell cytokines. Our analysis revealed that MM patients exhibited immune alterations in all studied immune subsets. Compared to HI, MM patients had a significantly lower proportion of CD4 + T cells (19.55% vs. 40.85%; p &lt; 0.001) and CD4 + iNKT cells (18.8% vs. 40%; p &lt; 0.001), within B cells an increased proportion of CD21LCD38L subset (4.5% vs. 0.4%; p &lt; 0.01) and decreased level of memory cells (unswitched 6.1% vs. 14.7%; p &lt; 0.001 and switched 7.8% vs. 11.2%; NS), NK cells displaying signs of activation and exhaustion characterised by a more than 2-fold increase in SLAMF7 MFI (p &lt; 0.001), decreased expression of NKG2D (MFI) and NKp46 (%) on CD16 + 56 + and CD16 + 56- subset respectively (p &lt; 0.05), Effective immunotherapy needs to consider these immune defects and monitoring of the immune status of MM patients is essential to define better interventions in the future.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Annals of Hematology

ISSN

0939-5555

e-ISSN

1432-0584

Svazek periodika

103

Číslo periodika v rámci svazku

12

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

11

Strana od-do

5615-5625

Kód UT WoS článku

001239242700001

EID výsledku v databázi Scopus

2-s2.0-85195180393